[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"research-subjects\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:research-subjects":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":39,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100644320","research-patients-and-clinical-research-nurses-exploring-their-experiences-of-taking-part-in-clinical-research-in-the-nhs-100644320",false,"NCT07663058","Research-patientS and Clinical researcH Nurses: Exploring Their Experiences of tAking paRt in Clinical resEarch in the NHS","SHARE","Inclusion Criteria:\n\nINCLUSION CRITERIA FOR RESEARCH-PATIENTS\n\n* Research-patients aged above 18 years old.\n* Research-patients currently participating or have previously participated in adult clinical research at the age of 18 (or over) at GSTT.\n* Research-patients who are willing and able to provide informed consent.\n\nINCLUSION CRITERIA FOR CRNS Clinical research nurses (CRNs) currently working in adult clinical research at Guys and St Thomas' NHS Foundation Trust.\n\n• CRN willing and able to give consent.\n\nExclusion Criteria:\n\nEXCLUSION CRITERIA FOR RESEARCH-PATIENTS\n\n* Patients who showed an interest in taking part in research but were not recruited, e.g. due to screen failure, or ineligibility.\n* Research-patients recruited to research via proxy consent, e.g., next of kin.\n* Patients unable to provide informed consent, e.g., lacking mental capacity.\n* Research-patients considered vulnerable or at risk of harm, by the research team\n* Research-patients taking part in mental health or maternity trials or studies\n* Research-patients not fluent in English or not able to converse well in English\n\nEXCLUSION CRITERIA FOR CRNS\n\n* Clinical research midwives and clinical research nurses working in mental health, maternity, and paediatric research are excluded from this study.\n* CRNs not willing or unable to give consent.",true,"ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","This PhD explores the views of clinical research nurses (CRNs) and research-patients as they take part in clinical research within their respective roles, i.e., as a specialised staff member and as a patient volunteer. Clinical research is supported by NHS England as the best way to improve patient care by finding out whether a new treatment is better than what is available. CRNs are specialist nurses who manage and coordinate clinical research. CRNs are responsible for the safe running of research; they ensure the right information is collected for the research\u002Ftrial to be successful. CRNs support the well-being of research-patients, by taking note of any new, or existing healthcare needs of research-patients while they take part in research. CRNs coordinate the activities that research requires, biological samples, scans, documentation. Balancing their responsibility towards research-patients, on the one hand, and research management, on the other, can bring unique challenges for the CRN. CRNs can feel conflicted between these two responsibilities, e.g., when they think that a drug trial, or the research activities in a study is at odds with the research-patient's best interest despite the research-patient's consent to take part in research. CRNs are tasked with maintaining\u002Ffacilitating recruitment of research-patients, this can be a challenging aspect of their role especially if they feel pressured to approach patients to take part in research. Currently, we know little about how CRNs balance these two responsibilities, or what other problems CRNs have in their everyday role when balancing these responsibilities. Finding out more about these aspects of the CRN role is important because it may not only improve job experience but can also give a better understanding of what can be changed to improve how CRN perform their role which could ultimately improve research-patients' experience of taking part in research. To address this issue, this PhD will explore CRNs and research-patients' views about clinical research, the challenges CRNs face, how CRNs balance their responsibilities, and what role does the relationship between CRNs, and research-patients play overall in what they say about their experience of taking part in clinical research. The researcher will interview and shadow CRNs and research-patients at a central NHS Hospital. This is a LISS\u002FESRC funded PhD at King's College London and supported by Guy's and St Thomas NHS Foundation Trust.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38],"Experiences","Lived Experiences","Research Participation","Research Subjects","Nurse's Role","Research Ethics","Therapeutic Misconception","Clinical Research Nurses","Research Nurses","Moral Distress","Ethical Dilemma","Research-Patients","Research Nurse and Research-Patient Interactions","Research Experience",[32,36,38,31,40,41],"Ethical Challenges","CRN Dual Role","NOT_YET_RECRUITING","2026-06-23",{"date":45,"type":46},"2026-06-26","ACTUAL",{"date":48,"type":21},"2026-08-30",{"date":50,"type":21},"2028-12-30",{"name":52,"class":53},"Guy's and St Thomas' NHS Foundation Trust","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":4,"leadSponsor":81,"locationsCount":54},"100054778","collection-and-distribution-of-blood-components-from-healthy-donors-for-in-vitro-research-use-100054778","NCT00001846","Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use","* ELIGIBILITY CRITERIA:\n\nDonors must meet the eligibility criteria for volunteer blood donation, defined in the Code of Federal Regulations 21 CFR 640, and AABB Standards as modified in the 2007 FDA\u002FCBER Guidance Document: Eligibility Criteria for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products, with the exception of foreign travel history and other conditions, as noted below:\n\n* Ability of subject to understand, ask questions, and the willingness to provide written informed consent\n* Age greater than or equal to 18 years\n* Weight greater than 110 pounds\n* Female subjects should not be pregnant\n* No known heart, lung, kidney disease, or bleeding disorders\n* No history of sickle cell disease\n* No history of engaging in high-risk activities for exposure to the AIDS virus, as defined in the AABB Donor Education Materials distributed to all donors. Deferral periods for high-risk activities (MSM, IV drug use or receipt of money or drugs in exchange for sex) will not exceed the corresponding deferral period as defined for allogeneic blood donors.\n* No history of malaria in the past 12 months\n* Donors who have a family history of CJD, donors who have undergone tattooing or body piercing, donors who have received a graft such as bone, skin or dura mater, donors who are taking finasteride or retinoids, and donors who have had sexual contact within the past 12 months with a person who has symptomatic hepatitis C infection or donors who have lived with a person who has hepatitis in the last 12 months, are similarly eligible for research-use only donations on this protocol.\n* Donors who have traveled to Europe, Africa, Asia, and areas of South America, who are rendered ineligible for allogeneic donation due to malarial risk, Zika risk and vCJD risk, are eligible for research donations\n* Donors with a history of repeat false positive HTLV I\u002FII, who are rendered ineligible for allogeneic donation, are eligible for research donations.\n* Donors with a positive antibody to hepatitis B core antigen (anti-HBc) only, without other positive infectious disease markers,are eligible for research donations.\n* Donors with HLA antibodies are eligible for research donations\n* Donors who have received an experimental drug, agent, or vaccine, and who are referred for a research blood, plasma or leukocyte collection, specifically because they were given this drug, agent, or vaccine, are acceptable only if their research product is collected for use by the PI who administered the experimental drug, agent, or vaccine. Otherwise, they are deferred for one year after receiving an experimental drug, agent, or vaccine.\n* Donors who have received a xenotransplant are eligible for research donations.\n* Granulocyte donors may not receive dexamethasone if they have poorly controlled hypertension or diabetes, or if they have a history of cataracts. Hetastarch (also known as hydroxyethyl starch or \"HES\") and dexamethasone may elevate blood pressure and raise blood glucose levels, and repetitive steroid administration may increase the risk of posterior subcapsular cataract formation or progression.\n* Granulocyte donors must have an estimated glomerular filtration (eGFR) rate of \\> 45ml\u002Fmin\u002F1.73m\\^2.\n* Granulocyte donors may not receive filgrastim if they have a history or symptoms of coronary heart disease.\n\nInvestigators are informed that eligibility standards for research donors differ from those for transfusion donors through an electronic \"User Agreement\" which they electronically sign when they register to receive blood components on this protocol.","100 Years",{"count":63,"type":21},5000,"This protocol is designed to provide a mechanism for the Department of Transfusion Medicine, Clinical Center to collect and process blood components from paid, healthy volunteer donors for distribution to NIH intramural investigators and FDA researchers for in vitro laboratory use. Donors meeting research donor eligibility criteria will be recruited to donate blood and blood components by standard phlebotomy and apheresis techniques. The investigational nature of the studies in which their blood will be used, and the risks and discomforts of the donation process will be carefully explained to the donors, and a signed informed consent document will be obtained. Donors will be compensated according to an established schedule based on the duration and discomfort of the donation. NIH and FDA investigators requesting blood components for research use will be required to submit an electronic (Web-based) memo of request, briefly describing the nature of the research, and providing assurance that samples provided through this protocol will be used solely for in vitro and not for in vivo research. This protocol also provides a detailed schema for careful and frequent laboratory safety monitoring of repeat research apheresis donors.\n\nBlood components for research use will be distributed with a unique product number, and the DTM principal and associate investigators will serve as the custodians of the code that links the product with a donor s identity. The nature of the in vitro studies in which the blood and components collected in this study will be used is not the subject of this protocol, and is not possible to describe, since it involves basic investigative efforts in greater than 170 different NIH and FDA laboratories. The intent of this protocol is not to approve the research itself, but to provide adequate and complete informed consent for the donor, and to assure that the education, counseling, and protection of the study subjects (research blood donors) is performed in accordance with IRB, OHSR, OPRR and other applicable Federal regulatory standards...",[66,28,67],"Blood Donors","Apheresis",[69,70,71,72,73,74],"Volunteer Donor","Research Samples","Leukapheresis","Plateletpheresis","Plasmapheresis","Natural History","RECRUITING","2026-06-17",{"date":78,"type":46},"2026-06-18",{"date":80,"type":46},"2001-01-11",{"name":82,"class":83},"National Institutes of Health Clinical Center (CC)","NIH",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":16,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100633235","giving-children-a-voice-in-paediatric-anaesthesia-100633235","NCT07524049","Giving Children a Voice in Paediatric Anaesthesia","Patient, Parent and Clinician Voices - Establishing National and International Research Priorities for Paediatric Anaesthesia and Perioperative Medicine","TR-VP26","Inclusion Criteria:\n\n* Patients aged 6-16 years\n* Caregivers of patients aged 6-16 years\n* Clinicians working in paediatric perioperative medicine\n\nExclusion Criteria:\n\n* Patients \\\u003C6 and \\>16 years\n* Residence not in Switzerland\n* Inability to understand one of the 3 study languages (german, french, italian)","6 Years",{"count":94,"type":21},1040,"This project will identify the research priorities for paediatric anaesthesia and perioperative medicine in participating countries and highlight areas where further research and information can be provided to optimise the experience of children undergoing medical interventions.\n\nThis is expected to have significant positive impacts on patient and family engagement and interest in research within the community and aids to plan patient\u002F family-centred studies.",[97,98,99,100,101,28],"Perioperative Care","Pediatric Anesthesia","Pain Management","Anxiety","Research Agenda",[103,104,105,106,107,108],"perioperative medicine","pediatric anesthesia","patient perspective","parent perspective","research priorities","survey","2026-04-09",{"date":111,"type":46},"2026-04-13",{"date":113,"type":21},"2026-04-27",{"date":115,"type":21},"2027-12-31",{"name":117,"class":53},"Insel Gruppe AG, University Hospital Bern",7]